Phase 4
Completed N=14
Varenicline Effects In Schizophrenic Smokers
Schizophrenia · Tobacco Use · Nicotine Dependance
Source: ClinicalTrials.gov NCT00548470 ↗
Enrolled (actual)
14
Serious AEs
0.0%
Results posted
Sep 2017
Primary outcomePrimary: Self Report of Smoking — 36.45; 17.25; 12.52 Cigarettes
◆ Published Evidence
Highly cited
106citations · ~6 / year
Cognitive and antismoking effects of varenicline in patients with schizophrenia or schizoaffective disorder.
Summary
This is an open label pre-post study of the effects of clinical treatment with varenicline on 1) decreasing smoking in schizophrenic patients, 2) improving selected cognitive measures in schizophrenic patients, and 3) psychopathology in schizophrenic patients. Patients are assessed on subjective and objective measures of smoking, selected cognitive measures, and special chemical measures, during baseline testing and during 8 weeks of treatment with varenicline (1-2 mg/day).
Linked Publications
-
Cognitive and antismoking effects of varenicline in patients with schizophrenia or schizoaffective disorder.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Self Report of Smoking |
36.45; 17.25; 12.52 | — |
| PRIMARY CO (Carbon Monoxide) Breathalyzer Level |
8.97; 5.7; 4.85 | — |
| PRIMARY Plasma Cotinine |
362.25; 181.75; 200.25 | — |
| SECONDARY RBANS Neuropsychological Battery |
59.00; 59.17; 15.75; 19.50; 73.58; 63.50 | — |
| SECONDARY Change From Baseline in Psychiatric Symptoms |
56.57; 55.58; 12.58; 12.00 | — |
Eligibility Criteria
Inclusion Criteria
- Clinical Diagnosis of Schizophrenia or Schizoaffective Psychosis
- Recent History of Cigarette smoking
- Ages 18-65
Data sourced from ClinicalTrials.gov (NCT00548470) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.